Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis

被引:3
作者
Li, Sheng-li [1 ]
Xu, Peng [2 ]
Zhang, Lei [2 ]
Sun, Gui-xiang [3 ]
Lu, Zhao-jun [3 ]
机构
[1] Xuzhou Med Coll, Affiliated Hosp, Informat Ctr, Stat Off, Xuzhou 221004, Peoples R China
[2] Xuzhou Med Coll, Affiliated Hosp, Dept Radiol, Xuzhou 221004, Peoples R China
[3] Xuzhou Med Coll, Sch Publ Hlth, Xuzhou 221004, Peoples R China
来源
HIV CLINICAL TRIALS | 2014年 / 15卷 / 06期
关键词
efavirenz; HIV-1; meta-analysis; non-nucleoside reverse transcriptase inhibitor; rilpivirine; HIV-1-INFECTED PATIENTS; VS; EFAVIRENZ; TMC278; ECHO; PHASE-3; THRIVE; EFFICACY; RECOMMENDATIONS; GUIDELINES; RESISTANCE;
D O I
10.1310/hct1506-261
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: The aim of this study was to determine the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1. Methods: We ran duplicate searches of multiple databases and searchable Web sites of major HIV conferences (May to October 2013) to identify randomized controlled trials reporting the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1. Reference lists from retrieved articles were also reviewed. Data were extracted independently in duplicate using predefined data fields. All analyses used random effects models to calculate the summary treatment effect estimates. Results: Four randomized controlled trials with a total of 2,522 patients were included. The primary efficacy endpoint was the proportion of patients with confirmed HIV-1 RNA levels of <50 copies/mL (viral load) at 48 weeks. Rilpivirine demonstrated noninferior antiviral efficacy in viral load comparable with efavirenz at 48 weeks (relative risk [RR], 1.03; 95% CI, 0.99-1.07). The mean changes from baseline in CD4 count were similar in both rilpivirine and efavirenz (RR, 1.05; 95% CI, 0.85-1.24). Rilpivirine showed higher and significant difference in virological failure rates compared with the efavirenz group (RR, 1.70; 95% CI, 1.21-2.38). The incidences of the most commonly reported adverse events related to study medication, including rash and neurological events, were lower with rilpivirine than with efavirenz (RR, 0.11; 95% CI, 0.03-0.33; RR, 0.52; 95% CI, 0.45-0.60, respectively). Conclusions: Current evidence suggests a range of favorable effects and a generally favorable safety profile of rilpivirine in treatment-naive adults infected with HIV-1 at week 48.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
[41]   Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket [J].
Gu, Shuang-Xi ;
Xiao, Ting ;
Zhu, Yuan-Yuan ;
Liu, Gen-Yan ;
Chen, Fen-Er .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 174 :277-291
[42]   Multiple drugs and multiple targets: An analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT [J].
Minkara, Mona S. ;
Davis, Pamela H. ;
Radhakrishnan, Mala L. .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2012, 80 (02) :573-590
[43]   A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy [J].
Lake, Jordan E. ;
McComsey, Grace A. ;
Hulgan, Todd M. ;
Wanke, Christine A. ;
Mangili, Alexandra ;
Walmsley, Sharon L. ;
Boger, M. Sean ;
Turner, Ralph R. ;
McCreath, Heather E. ;
Currier, Judith S. .
AIDS PATIENT CARE AND STDS, 2012, 26 (09) :532-540
[44]   Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: an update on a systematic review and network meta-analysis [J].
Nickel, Katharina ;
Halfpenny, Nicholas J. A. ;
Snedecor, Sonya J. ;
Punekar, Yogesh Suresh .
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[45]   HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen [J].
Martinez, V ;
Marcelin, AG ;
Morini, JP ;
Deleuze, J ;
Krivine, A ;
Gorin, I ;
Yerly, S ;
Perrin, L ;
Peytavin, G ;
Calvez, V ;
Dupin, N .
AIDS, 2005, 19 (10) :1065-1069
[46]   Identification of a Novel Sulfonamide Non-Nucleoside Reverse Transcriptase Inhibitor by a Phenotypic HIV-1 Full Replication Assay [J].
Kim, Tae-Hee ;
Ko, Yoonae ;
Christophe, Thierry ;
Cechetto, Jonathan ;
Kim, Junwon ;
Kim, Kyoung-Ae ;
Boese, Annette S. ;
Garcia, Jean-Michel ;
Fenistein, Denis ;
Ju, Moon Kyeong ;
Kim, Junghwan ;
Han, Sung-Jun ;
Kwon, Ho Jeong ;
Brondani, Vincent ;
Sommer, Peter .
PLOS ONE, 2013, 8 (07)
[47]   Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients [J].
Khanna, N ;
Klimkait, T ;
Schiffer, V ;
Irigoyen, J ;
Telenti, A ;
Hirschel, B ;
Battegay, M .
AIDS, 2000, 14 (07) :791-799
[48]   Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies [J].
Molina, Jean Michel ;
Ene, Luminita ;
Cahn, Pedro ;
Faetkenheuer, Gerd ;
Van Wijngaerden, Eric ;
Lombaard, Johan ;
Zakharova, Natalia ;
Van Eygen, Veerle ;
Vanveggel, Simon ;
Van Solingen-Ristea, Rodica .
ANTIVIRAL THERAPY, 2021, 26 (6-8) :95-105
[49]   Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance [J].
Towner, William J. ;
Cassetti, Isabel ;
Domingo, Pere ;
Nijs, Steven ;
Kakuda, Thomas N. ;
Vingerhoets, Johan ;
Woodfall, Brian .
ANTIVIRAL THERAPY, 2010, 15 (06) :803-816
[50]   Effectiveness and safety of an abacavir/lamivudine plus rilpivirine regimen for the treatment of HIV-1 infection in naive patients [J].
Curran, Adrian ;
Rojas, Jhon ;
Cabello, Alfonso ;
Troya, Jesus ;
Imaz, Arkaitz ;
Domingo, Pere ;
Martinez, Esteban ;
Ryan, Pablo ;
Gorgolas, Miguel ;
Podzamczer, Daniel ;
Knobel, Hernando ;
Gutierrez, Felix ;
Ribera, Esteban .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (12) :3510-3514